oxyphenbutazone

Indications

• postoperative ocular inflammation
• superficial eye injuries
• episcleritis

Adverse effects

• bone marrow suppression*

* withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression

• drug adverse effects of NSAIDs

Laboratory

• oxyphenbutazone in blood
• oxyphenbutazone in serum/plasma
• oxyphenbutazone in urine

More general terms

• non-steroidal anti-inflammatory agent (NSAID)
• ophthalmic agent (eyedrops)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4641